[1] Sung H, Ferlay J, Siegel RL, et al.  Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.   doi: 10.3322/caac.21660
[2]

Zhang YT, Rumgay H, Li MM, et al. Nasopharyngeal cancer incidence and mortality in 185 countries in 2020 and the projected burden in 2040: population-based global epidemiological profiling[J/OL]. JMIR Public Health Surveill, 2023, 9: e49968[2023-04-10]. https://publichealth.jmir.org/2023/1/e49968. DOI: 10.2196/49968.
[3]

Liang YJ, Liu LT, Li Y, et al. Association of treatment advances with survival rates in pediatric patients with nasopharyngeal carcinoma in China, 1989-2020[J/OL]. JAMA Netw Open, 2022, 5(3): e220173[2023-04-10]. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789571. DOI: 10.1001/jamanetworkopen.2022.0173.
[4] Du XJ, Wang GY, Zhu XD, et al.  Refining the 8th edition TNM classification for EBV related nasopharyngeal carcinoma[J]. Cancer Cell, 2024, 42: 1-10.   doi: 10.1016/j.ccell.2023.12.020
[5] Zhuo EH, Zhang WJ, Li HJ, et al.  Radiomics on multi-modalities MR sequences can subtype patients with non-metastatic nasopharyngeal carcinoma (NPC) into distinct survival subgroups[J]. Eur Radiol, 2019, 29(10): 5590-5599.   doi: 10.1007/s00330-019-06075-1
[6]

Tang LL, Chen YP, Chen CB, et al. The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma[J/OL]. Cancer Commun (Lond), 2021, 41(11): 1195−1227[2023-04-10]. https://onlinelibrary.wiley.com/doi/10.1002/cac2.12218. DOI: 10.1002/cac2.12218.
[7] Pfister DG, Spencer S, Adelstein D, et al.  Head and neck cancers, version 2. 2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020, 18(7): 873-898.   doi: 10.6004/jnccn.2020.0031
[8] Yang SS, Wu YS, Chen WC, et al.  Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma[J]. Eur J Nucl Med Mol Imaging, 2022, 49(3): 980-991.   doi: 10.1007/s00259-021-05540-8
[9] Dash SR, Kundu A, Kundu CN.  The role of viruses in cancer progression versus cancer treatment: a dual paradigm[J]. Life Sci, 2024, 341: 122506-.   doi: 10.1016/j.lfs.2024.122506
[10] Soret M, Bacharach SL, Buvat I.  Partial-volume effect in PET tumor imaging[J]. J Nucl Med, 2007, 48(6): 932-945.   doi: 10.2967/jnumed.106.035774
[11] Aggarwal BB, Vijayalekshmi RV, Sung B.  Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe[J]. Clin Cancer Res, 2009, 15(2): 425-430.   doi: 10.1158/1078-0432.Ccr-08-0149
[12] Xie P, Yue JB, Fu Z, et al.  Prognostic value of 18F-FDG PET/CT before and after radiotherapy for locally advanced nasopharyngeal carcinoma[J]. Ann Oncol, 2010, 21(5): 1078-1082.   doi: 10.1093/annonc/mdp430
[13] Hung TM, Wang HM, Kang CJ, et al.  Pretreatment 18F-FDG PET standardized uptake value of primary tumor and neck lymph nodes as a predictor of distant metastasis for patients with nasopharyngeal carcinoma[J]. Oral Oncol, 2013, 49(2): 169-174.   doi: 10.1016/j.oraloncology.2012.08.011
[14] Gihbid A, Salhi GC, El Alami I, et al.  Pretreatment [18F]FDG PET/CT and MRI in the prognosis of nasopharyngeal carcinoma[J]. Ann Nucl Med, 2022, 36(10): 876-886.   doi: 10.1007/s12149-022-01770-4
[15] Hung TM, Fan KH, Kang CJ, et al.  Lymph node-to-primary tumor standardized uptake value ratio on PET predicts distant metastasis in nasopharyngeal carcinoma[J]. Oral Oncol, 2020, 110: 104756-.   doi: 10.1016/j.oraloncology.2020.104756
[16] Shen EYL, Hung TM, Tsan DL, et al.  Utilization of the lymph node-to-primary tumor ratio of PET standardized uptake value and circulating Epstein-Barr virus DNA to predict distant metastasis in nasopharyngeal carcinoma[J]. Radiother Oncol, 2022, 177: 1-8.   doi: 10.1016/j.radonc.2022.05.004
[17]

Lin J, Xie GZ, Liao GX, et al. Prognostic value of 18F-FDG-PET/CT in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis[J/OL]. Oncotarget, 2017, 8(20): 33884−33896[2023-04-10]. https://www.oncotarget.com/article/13934/text. DOI: 10.18632/oncotarget.13934.
[18]

Chan SC, Yeh CH, Chang JTC, et al. Combing MRI perfusion and 18F-FDG PET/CT metabolic biomarkers helps predict survival in advanced nasopharyngeal carcinoma: a prospective multimodal imaging study[J/OL]. Cancers (Basel), 2021, 13(7): 1550[2023-04-10]. https://www.mdpi.com/2072-6694/13/7/1550. DOI: 10.3390/cancers13071550.
[19]

Yang ZY, Shi Q, Zhang YP, et al. Pretreatment 18F-FDG uptake heterogeneity can predict survival in patients with locally advanced nasopharyngeal carcinoma—a retrospective study[J/OL]. Radiat Oncol, 2015, 10: 4[2023-04-10]. https://ro-journal.biomedcentral.com/articles/10.1186/s13014-014-0268-5. DOI: 10.1186/s13014-014-0268-5.
[20]

Xiong SM, Dong LL, Cheng L. Neutrophils in cancer carcinogenesis and metastasis[J/OL]. J Hematol Oncol, 2021, 14(1): 173[2023-04-10]. https://jhoonline.biomedcentral.com/articles/10.1186/s13045-021-01187-y. DOI: 10.1186/s13045-021-01187-y.
[21] He JR, Shen GP, Ren ZF, et al.  Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma[J]. Head Neck, 2012, 34(12): 1769-1776.   doi: 10.1002/hed.22008
[22] Lu J, Chen XM, Huang HR, et al.  Detailed analysis of inflammatory cell infiltration and the prognostic impact on nasopharyngeal carcinoma[J]. Head Neck, 2018, 40(6): 1245-1253.   doi: 10.1002/hed.25104
[23]

Chen LS, Li MY, Xu T, et al. Prognostic value of neutrophils for patients with nasopharyngeal carcinoma[J/OL]. Laryngoscope Investig Otolaryngol, 2021, 6(2): 219−225[2023-04-10]. https://onlinelibrary.wiley.com/doi/10.1002/lio2.548. DOI: 10.1002/lio2.548.
[24] Szkandera J, Gerger A, Liegl-Atzwanger B, et al.  The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas[J]. Int J Cancer, 2014, 135(2): 362-370.   doi: 10.1002/ijc.28677
[25]

Li J, Jiang R, Liu WS, et al. A large cohort study reveals the association of elevated peripheral blood lymphocyte-to-monocyte ratio with favorable prognosis in nasopharyngeal carcinoma[J/OL]. PLoS One, 2013, 8(12): e83069[2023-04-10]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0083069. DOI: 10.1371/journal.pone.0083069.
[26] Liu LT, Liang YJ, Guo SS, et al.  Identifying distinct risks of treatment failure in nasopharyngeal carcinoma: study based on the dynamic changes in peripheral blood lymphocytes, monocytes, N classification, and plasma Epstein-Barr virus DNA[J]. Head Neck, 2022, 44(1): 34-45.   doi: 10.1002/hed.26897
[27] Ostroumov D, Fekete-Drimusz N, Saborowski M, et al.  CD4 and CD8 T lymphocyte interplay in controlling tumor growth[J]. Cell Mol Life Sci, 2018, 75(4): 689-713.   doi: 10.1007/s00018-017-2686-7
[28] Wang YQ, Chen YP, Zhang Y, et al.  Prognostic significance of tumor-infiltrating lymphocytes in nondisseminated nasopharyngeal carcinoma: a large-scale cohort study[J]. Int J Cancer, 2018, 142(12): 2558-2566.   doi: 10.1002/ijc.31279
[29]

Cai ZC, Jiang JL, Huang LJ, et al. The prognostic impact of combined tumor-infiltrating lymphocytes and pretreatment blood lymphocyte percentage in locally advanced nasopharyngeal carcinoma[J/OL]. Front Oncol, 2021, 11: 788497[2023-04-10]. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.788497/full. DOI: 10.3389/fonc.2021.788497.
[30] Marone G, Varricchi G, Loffredo S, et al.  Mast cells and basophils in inflammatory and tumor angiogenesis and lymphangiogenesis[J]. Eur J Pharmacol, 2016, 778: 146-151.   doi: 10.1016/j.ejphar.2015.03.088
[31] Grisaru-Tal S, Dulberg S, Beck L, et al.  Metastasis-entrained eosinophils enhance lymphocyte-mediated antitumor immunity[J]. Cancer Res, 2021, 81(21): 5555-5571.   doi: 10.1158/0008-5472.CAN-21-0839
[32] Zeng XJ, Liu GH, Pan YB, et al.  Development and validation of immune inflammation-based index for predicting the clinical outcome in patients with nasopharyngeal carcinoma[J]. J Cell Mol Med, 2020, 24(15): 8326-8349.   doi: 10.1111/jcmm.15097
[33]

Schlesinger M. Role of platelets and platelet receptors in cancer metastasis[J/OL]. J Hematol Oncol, 2018, 11(1): 125[2023-04-10]. https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0669-2. DOI: 10.1186/s13045-018-0669-2.
[34]

Li F, Xu T, Chen PL, et al. Platelet-derived extracellular vesicles inhibit ferroptosis and promote distant metastasis of nasopharyngeal carcinoma by upregulating ITGB3[J/OL]. Int J Biol Sci, 2022, 18(15): 5858−5872[2023-04-10]. https://www.ijbs.com/v18p5858.htm. DOI: 10.7150/ijbs.76162.
[35] Chen YP, Chen C, Mai ZY, et al.  Pretreatment platelet count as a predictor for survival and distant metastasis in nasopharyngeal carcinoma patients[J]. Oncol Lett, 2015, 9(3): 1458-1466.   doi: 10.3892/ol.2015.2872
[36]

Mishra D, Banerjee D. Lactate dehydrogenases as metabolic links between tumor and stroma in the tumor microenvironment[J/OL]. Cancers (Basel), 2019, 11(6): 750[2023-04-10]. https://www.mdpi.com/2072-6694/11/6/750. DOI: 10.3390/cancers11060750.
[37] Dhup S, Dadhich RK, Porporato PE, et al.  Multiple biological activities of lactic acid in cancer: influences on tumor growth, angiogenesis and metastasis[J]. Curr Pharm Des, 2012, 18(10): 1319-1330.   doi: 10.2174/138161212799504902
[38]

Huang L, Sim AYL, Wu YZ, et al. Lactate dehydrogenase kinetics predict chemotherapy response in recurrent metastatic nasopharyngeal carcinoma[J]. Ther Adv Med Oncol, 2020, 12: 1758835920970050. DOI: 10.1177/1758835920970050.
[39] Liaw CC, Wang CH, Huang JS, et al.  Serum lactate dehydrogenase level in patients with nasopharyngeal carcinoma[J]. Acta Oncol, 1997, 36(2): 159-164.   doi: 10.3109/02841869709109224
[40] Wan XB, Wei L, Li H, et al.  High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma[J]. Eur J Cancer, 2013, 49(10): 2356-2364.   doi: 10.1016/j.ejca.2013.03.008
[41] Bellelli A, Tame JRH.  Hemoglobin allostery and pharmacology[J]. Mol Aspects Med, 2022, 84: 101037-.   doi: 10.1016/j.mam.2021.101037
[42] Yuan M, Liang S, Zhou Y, et al.  A robust oxygen-carrying hemoglobin-based natural sonosensitizer for sonodynamic cancer therapy[J]. Nano Lett, 2021, 21(14): 6042-6050.   doi: 10.1021/acs.nanolett.1c01220
[43] Prosnitz RG, Yao B, Farrell CL, et al.  Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer[J]. Int J Radiat Oncol Biol Phys, 2005, 61(4): 1087-1095.   doi: 10.1016/j.ijrobp.2004.07.710
[44]

Guo SS, Tang LQ, Chen QY, et al. Is hemoglobin level in patients with nasopharyngeal carcinoma still a significant prognostic factor in the era of intensity-modulated radiotherapy technology?[J/OL]. PLoS One, 2015, 10(8): e0136033[2023-04-10]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0136033. DOI: 10.1371/journal.pone.0136033.
[45]

Zhang LL, Zhou GQ, Li YY, et al. Combined prognostic value of pretreatment anemia and cervical node necrosis in patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: a large-scale retrospective study[J/OL]. Cancer Med, 2017, 6(12): 2822−2831[2023-04-10]. https://onlinelibrary.wiley.com/doi/10.1002/cam4.1233. DOI: 10.1002/cam4.1233.
[46] Ruan GT, Xie HL, Yuan KT, et al.  Prognostic value of systemic inflammation and for patients with colorectal cancer cachexia[J]. J Cachexia Sarcopenia Muscle, 2023, 14(6): 2813-2823.   doi: 10.1002/jcsm.13358
[47]

Tang LQ, Hu DP, Chen QY, et al. Elevated high-sensitivity C-reactive protein levels predict decreased survival for nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era[J/OL]. PLoS One, 2015, 10(4): e0122965[2023-04-10]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0122965. DOI: 10.1371/journal.pone.0122965.
[48]

Chen RW, Zhou Y, Yuan YJ, et al. Effect of CRP and kinetics of CRP in prognosis of nasopharyngeal carcinoma[J/OL]. Front Oncol, 2019, 9: 89[2023-04-10]. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.00089/full. DOI: 10.3389/fonc.2019.00089.
[49] Yang HF, Wang K, Liang Z, et al.  Prognostic role of pre-treatment serum albumin in patients with nasopharyngeal carcinoma: a meta-analysis and systematic review[J]. Clin Otolaryngol, 2020, 45(2): 167-176.   doi: 10.1111/coa.13454
[50] Gao N, Yang RN, Meng Z, et al.  The prognostic value of C-reactive protein/albumin ratio in nasopharyngeal carcinoma: a meta-analysis[J]. Biosci Rep, 2018, 38(6): BSR20180686-.   doi: 10.1042/BSR20180686
[51]

Yang SS, Zhao K, Ding X, et al. Prognostic significance of hematological markers for patients with nasopharyngeal carcinoma: a meta-analysis[J/OL]. J Cancer, 2019, 10(11): 2568−2577[2023-04-10]. https://www.jcancer.org/v10p2568.htm. DOI: 10.7150/jca.26770.
[52] An X, Ding PR, Wang FH, et al.  Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma[J]. Tumour Biol, 2011, 32(2): 317-324.   doi: 10.1007/s13277-010-0124-7
[53]

Chen C, Sun P, Dai QS, et al. The Glasgow Prognostic Score predicts poor survival in cisplatin-based treated patients with metastatic nasopharyngeal carcinoma[J/OL]. PLoS One, 2014, 9(11): e112581[2023-04-10]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0112581. DOI: 10.1371/journal.pone.0112581.
[54] Jiang R, Zou X, Hu W, et al.  The elevated pretreatment platelet-to-lymphocyte ratio predicts poor outcome in nasopharyngeal carcinoma patients[J]. Tumour Biol, 2015, 36(10): 7775-7787.   doi: 10.1007/s13277-015-3505-0
[55]

Li XH, Chang H, Xu BQ, et al. An inflammatory biomarker-based nomogram to predict prognosis of patients with nasopharyngeal carcinoma: an analysis of a prospective study[J/OL]. Cancer Med, 2017, 6(1): 310−319[2023-04-10]. https://onlinelibrary.wiley.com/doi/10.1002/cam4.947. DOI: 10.1002/cam4.947.
[56] Ma MZ, Weng MZ, Chen F, et al.  Systemic inflammation score is a prognostic marker after curative resection in gastric cancer[J]. ANZ J Surg, 2019, 89(4): 377-382.   doi: 10.1111/ans.15103
[57]

Jiang WJ, Chen Y, Huang J, et al. Systemic immune-inflammation index predicts the clinical outcome in patients with nasopharyngeal carcinoma: a propensity score-matched analysis[J/OL]. Oncotarget, 2017, 8(39): 66075−66086[2023-04-10]. https://www.oncotarget.com/article/19796/text. DOI: 10.18632/oncotarget.19796.
[58] Chen Y, Jiang WJ, Xi D, et al.  Development and validation of nomogram based on SIRI for predicting the clinical outcome in patients with nasopharyngeal carcinomas[J]. J Investig Med, 2019, 67(3): 691-698.   doi: 10.1136/jim-2018-000801
[59]

Zeng XJ, Liu GH, Pan YB, et al. Prognostic value of clinical biochemistry-based indexes in nasopharyngeal carcinoma[J/OL]. Front Oncol, 2020, 10: 146[2023-04-10]. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00146/full. DOI: 10.3389/fonc.2020.00146.
[60] Zhong LT, Li CM, Ren YY, et al.  Prognostic value of 18F-fluorodeoxyglucose PET parameters and inflammation in patients with nasopharyngeal carcinoma[J]. Oncol Lett, 2017, 14(4): 5004-5012.   doi: 10.3892/ol.2017.6816
[61] Xiao BB, Lin DF, Sun XS, et al.  Nomogram for the prediction of primary distant metastasis of nasopharyngeal carcinoma to guide individualized application of FDG PET/CT[J]. Eur J Nucl Med Mol Imaging, 2021, 48(8): 2586-2598.   doi: 10.1007/s00259-020-05128-8
[62] Xian WJ, Feng YL, Wang Y, et al.  Usefulness of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography combined with the platelet-lymphocyte ratio in predicting the prognosis of nasopharyngeal carcinoma[J]. Br J Radiol, 2022, 95(1129): 20210279-.   doi: 10.1259/bjr.20210279
[63]

Chiang CL, Guo QJ, Ng WT, et al. Prognostic factors for overall survival in nasopharyngeal cancer and implication for TNM staging by UICC: a systematic review of the literature[J/OL]. Front Oncol, 2021, 11: 703995[2023-04-10]. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.703995/full. DOI: 10.3389/fonc.2021.703995.